As Senior Safety Advisor you will be a key player in the safety surveillance and development of one of LEO Pharma’s new biologics for the treatment of atopic dermatitis. You will become part of a team of 6 Safety Advisors working with an investigational, fully human monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis. The product specifically blocks the effects of the cytokine IL-13, which plays an important role in the pathophysiology of atopic dermatitis – one of the most common chronic, inflammatory skin diseases.
LEO Pharma has embarked on a growth journey to become the preferred dermatology care partner in the world, dedicated to help people achieve healthy skin. We have recently introduced our 2025 strategy, which aims to accelerate our efforts in innovative therapeutics while strengthening our established portfolio and our global footprint in medical dermatology. Dermatology is an area of rapid growth and LEO Pharma is rapidly changing from primarily focusing on topical treatments, to being at the forefront of scientific advancements to help patients.
We are offering a job with considerable individual responsibility, challenges, and the opportunity to develop your professional and personal competencies. As Senior Safety Advisor, your main focus is to be globally responsible for effective safety risk management processes with main tasks being:
Global Safety Surveillance consists of 30+ dynamic colleagues striving to safeguard our patients and to improve the quality of our processes and developing our competencies to meet the need of the patients and other stakeholders, internally as well as externally. We are driven by a high level of integrity, science, passion for our work and an open minded approach. We
The position is placed in the LEO Pharma headquarters in Ballerup.
Please contact Director, Head of Global Safety Surveillance Christina Virkelyst Tvermoes at +45 41736582.
Please send your application no later than 3 December 2018.
Interviews will be held on an ongoing basis.